<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166530</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-089</org_study_id>
    <secondary_id>MK0653A-089</secondary_id>
    <secondary_id>2005_059</secondary_id>
    <nct_id>NCT00166530</nct_id>
  </id_info>
  <brief_title>EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)</brief_title>
  <official_title>A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      In patients with coronary artery disease and a LDL-C level between 2.5 mmol/L and 5.0 mmol/L
      on a stable (&gt; 4 weeks) statin starting dose (simvastatin 20 mg or atorvastatin 10 mg),
      investigate what the LCL-C lowering efficacy is of doubling the statin dose (to 40 mg
      simvastatin or 20 mg atorvastatin) versus a combination tablet of ezetimibe 10 mg plus
      simvastatin 20 mg once daily for 12 weeks. It is postulated that more patients reach their
      LDL-C treatment goal with the combination tablet compared to doubling the starting dose.
      Furthermore, the effect of both treatment regimens on other lipid parameters, safety and
      LDL-subfractions will be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with simvastatin 20 mg or atorvastatin 10 mg were randomized to (1) double statin
      dose (to 40 mg simvastatin or 20 mg atorvastatin) or (2) switch to a combination tablet of
      ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Switching to a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg is superior to doubling the statin dose as demonstrated by the percentage of patients reaching goal after 12 weeks of treatment.</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Switching to a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg will lower LDL-C more than doubling the statin dose as demonstrated by the percentage change from treated baseline in total and LDL-cholesterol after 12 weeks of treatment.</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">367</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: Active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets</description>
    <arm_group_label>2</arm_group_label>
    <other_name>MK0653A</other_name>
    <other_name>Vytorin®</other_name>
    <other_name>INEGY™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0733</other_name>
    <other_name>Zocor®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>20 mg atorvastatin once daily for 12 weeks. Tablets</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female 18 years of age.

          -  Patient is on a stable daily statin starting dose for the past 4 weeks of either:
             atorvastatin 10 mg or; simvastatin 20 mg

          -  lipid values while on statin monotherapy treatment: LDL-C level of &gt; 2.5 mmol/L to *
             5.0 mmol/L, triglycerides &lt; 4.0 mmol/L and total cholesterol &lt; 7.0 mmol/L.

          -  Patient with established coronary artery disease such as stable angina; history of
             myocardial infarction; history of percutaneous coronary intervention (PTCA with or
             without stent placement); coronary stenosis on angiography; history of unstable angina
             or non-Q wave myocardial infarction; history of coronary artery bypass graft surgery
             (CABG); positive MIBI scan. Patients have to be in a stable medical condition.

        Exclusion Criteria:

          -  Patients in whom cholesterol lowering medication regime has changed in the previous 4
             weeks.

          -  Patients who have been treated with any other investigational drug within 3 months of
             Visit 1.

          -  Patients who are pregnant or lactating.

          -  Any condition or situation which, in the opinion of the investigator, might pose a
             risk to the patient or interfere with participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://www.merck.com/clinical-trials/policies-perspectives.html</url>
    <description>Click here to access a synopsis of the study results.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Links</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

